Group items tagged

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors. "Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant Gastroenterologist at NHS Greater Glasgow and Clyde. "Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year. The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their condition." The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for upadacitinib in UC in July 2022.

HPV -một loại vi rút gây u nhú ở người, được xem là nguyên nhân chính gây nên sùi mào gà. Những u nhú này mọc ở bộ phận sinh dục có tiết dịch mủ mùi khó chịu nếu "vùng kín" không được vệ sinh kịp thời. Hơn nữa, những tổn thương sùi mào gà này có thể khiến người bệnh cảm thấy khó khăn đi lại bởi nó mọc quá nhiều gây sang chấn.

Bệnh lý ở cổ tử luôn là nỗi ám ảnh với nhiều chị em phụ nữ. Một trong số đó là polyp cổ tử cung. Polyp cổ tử cung nếu không được sớm chữa trị có thể dẫn tới những ảnh hưởng tới sức khoẻ sinh sản của chị em. Đặc biệt với những phụ nữ đang mang thai, tình trạng polyp cổ tử cung khi mang thai càng cần được chú ý. Thực chất, polyp cổ tử cung xuất phát từ những khối u nhỏ lành tính do sự gia tăng của các tế bào tuyến lớp niêm mạc cổ tử cung, khối u này phát triển từ mặt trong hoặc mặt ngoài của cổ tử cung và ở mỗi trường hợp chúng lại có kích thước khác nhau.

Dr. Michael Omidi MD, along with his brother Julian Omidi, is cofounder of No More Poverty, an organization promoting the works of charities that strive to end poverty and the conditions that cause poverty both in the U. S. and abroad. In this article, Dr. Michael Omidi discusses the Omidi brothers' sponsorship of Jessica's Hope Project, a foundation that sends healthy care packages to U.S. soldiers overseas.

Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business Factbook 2017" found that the U.S. legal-weed market is expected to grow by 45% in 2018, and an aggregate of 300% between 2016 and 2021. If these projections are accurate, we could be talking about a $17 billion market by 2021. With growth like this, it's no wonder why marijuana stocks have gone through the roof in recent years.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

Online retail giant Amazon said on Tuesday (January 24) it is offering a $5 monthly subscription plan for U.S. Prime members that will cover a range of generic drugs and their doorstep delivery, furthering the ecommerce giant's push into healthcare. The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes and male pattern baldness, Vin Gupta, Amazon Pharmacy's chief medical officer, has said. However, customers enrolled in Medicare, Medicaid or any other government healthcare program will not be able to enrol in Amazon Pharmacy's RxPass service. The average Prime member would save about $100 per year with RxPass, John Love, vice president of Amazon Pharmacy, said. Amazon Prime members in most U.S. states can sign up for the program from January 24. The flat $5 charge would be without insurance and on top of the Prime membership fee, which costs $139 per year in the United States.

U.S. Customs and Border Protection (CBP) officers at the port of Cincinnati seized two unapproved shipments of weight loss drugs, including one from a UK pharmacy, last month. On 5 October, CBP officers seized a shipment declared as "cosmetic weight loss product" and found containing Mounjaro injectable pens of multiple doses (2.5mg, 5mg, and 7mg). The shipment, arriving from a UK pharmacy and heading to a residence in Ohio, violated the Federal Food, Drug, and Cosmetic Act (FDCA), according to a U.S. Customs and Border Protection report. Cincinnati CBP officers on 14 October intercepted another shipment, which was also destined for an Ohio residence. This shipment from Hong Kong contained 20 vials of Semaglutide 10 mg and 150 Tirzepatide 30 mg, with a domestic value of $45,450. LaFonda D. Sutton-Burke, Director of Field Operations-Chicago, stated that seizures involving these types of unapproved medications are a common occurrence that her officers see on a regular basis.

Looking for affordable and expert Ventricular Septal Defect (VSD) surgery outside the U.S. or U.K.? India offers world-class cardiac care starting from just $4,000-a fraction of the cost compared to Western countries. Ventricular Septal Defect Surgery in India | From $4000 vs USA/UK Prices.

Let's take a look at some of the insights found through research that help the policymakers and the system leaders identify the areas that need acute concentration while improving the overall US healthcare system of the country.

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

The U.S. Food & Health Supplement Stores Industry-Industry & Market Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2013 current and 2014 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S.

Juvenile arthritis involves 1 in 1,000 children in the U.S.A. The authentications are painfulness; hardness and swelling that last longer than 6 weeks and are not caused by an accidental injury or different sickness. Though the arthritis could initially introduce itself afterward an accidental injury or unwellness these are not the cause.

Somewhere in America, a women is raped every two minutes, according to the U.S. Department of Justice. One in four women are victims of rape or attempted rape, 84% of those women knew their attacker, 57% of the rapes have happened while on dates.

Somewhere in America, a women is raped every two minutes, according to the U.S. Department of Justice. One in four women are victims of rape or attempted rape, 84% of those women knew their attacker, 57% of the rapes have happened while on dates.

Drink Safe Technologies offers you the opportunity to safe guard your own drink by using our Drink Safe Coaster or Test Kit.

If you are looking for a more holistic wellness approach to your health then join him for a Healthy U class discussing how to manage a clean healthy diet and quick proper exercise in today's world.

If you are looking for a more holistic wellness approach to your health then join him for a Healthy U class discussing how to manage a clean healthy diet and quick proper exercise in today's world.